McAdams Wright Ragen Upgrades Dendreon (DNDN) to Hold
More News related to DNDN
- Dendreon (DNDN) May volatility elevated at 99 into data
- Dendreon (DNDN) volatility of 65 near two-year lows
- Dendreon (DNDN) Completes Submission of Amended Biologics License Application for PROVENGE®
- Dendreon (DNDN) Completes Submission of Biologics License Application for PROVENGE
- Dendreon Completes Submission of Biologics License Application for PROVENGE
More News related to Upgrades
- Sidoti & Co Initiates Coverage on Stratasys (SSYS) with a Neutral
- ThinkEquity Initiates Coverage on Sourcefire (FIRE) with a Buy
- Raymond James Initiates Coverage on Knight Capital (NITE) with a Market Perform
- Raymond James Initiates Coverage on International Game Technology (IGT) with a Market Perform
- Thomas Weisel Initiates Coverage on UQM Technologies (UQM) with an Overweight
McAdams Wright Ragen upgrades Dendreon (Nasdaq: DNDN) from Sell to Hold.
For more analyst ratings on DNDN click here.
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients.
Related Categories
UpgradesStocks Mentioned
+0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
